Shionogi won FDA approval for Xocova, an oral antiviral to prevent Covid-19 after exposure in people 12 and older who've been in contact with an infected individual.
June 1, 2026 12:50 PM EDT
FDA+
Shionogi wins US approval for first pill to prevent Covid following exposure
Zachary Brennan
Japan’s Shionogi on Monday said it won FDA approval for its oral antiviral to prevent Covid‑19 in adults and children older …
FDA approves Xocova for COVID-19 prevention after exposure
Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative
FDA approves Zaynich for complicated UTIs
FDA panel recommends updating Covid shots to target XFG strain
'USFDA nod for Zaynich a major boost'
China's Original Innovative Drug Cipepofol Approved for Marketing by the U.S. FDA
Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult Patients with Complicated Urinary Tract Infection Including Pyelonephritis
The FDA on Monday approved the first medication for COVID-19 prevention that people can take after they have been exposed to…
After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. | After a…
Drug arrives years after pandemic’s peak, but could still offer critical protection to vulnerable populations.
Ensitrelvir has already been approved as a prophylactic in Japan, with an FDA decision in the U.S. expected soon.
A group of scientists has confirmed the efficacy of a new oral anti-viral treatment, called CP-COV03 or Xafty, against COVID-19…
Un ensayo internacional publicado en The New England Journal of Medicine reveló el primer éxito comprobado de un antiviral oral…
